Women at increased risk of osteoporotic fractures should be treated with newly licensed injectable drug denosumab, if treatment with existing oral bisphosphonates is unsuitable.
Some women are unable to comply with the special instructions for administering oral bisphosphonates, for instance because of drug intolerance, contraindications or inability to abide by administration.
For these women, denosumab should be an option if they are at increased risk of fractures, said the draft NICE guidance.
NICE's appraisal committee said there was good evidence that denosumab would be a useful addition to treatment options.
Dr Carole Longson, NICE's health technology evaluation centre director, said: 'We hope that older women at increased risk of osteoporotic fractures who cannot take oral bisphosphonates will be considered for this drug.'